Results 21 to 30 of about 1,810,595 (288)
Gut microbiome on immune checkpoint inhibitor therapy and consequent immune-related colitis: a review [PDF]
Intestinal Research, 2023 Immune checkpoint inhibitors have dramatically revolutionized the therapeutic landscape for patients with advanced malignancies. Recently, convincing evidence has shown meaningful influence of gut microbiome on human immune system.
Sung Wook Hwang +2 more
doaj +1 more source
Frontiers in Oncology, 2022 Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of hepatocellular carcinoma over the past few years.
Qingqing Xie +4 more
doaj +1 more source
Immune Checkpoint Inhibitors and the Heart [PDF]
Frontiers in Cardiovascular Medicine, 2021 Immune checkpoint inhibitors (ICIs) represent a break-through treatment for a large number of cancer types. This treatment is increasingly being recommended. ICIs are prescribed for primary tumours and for metastases, adjuvant/neo-adjuvant therapy.
Diana Larisa Mocan-Hognogi +11 more
openaire +3 more sources
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Frontiers in Immunology, 2022 Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian +5 more
doaj +1 more source
Immune Checkpoint Inhibitors [PDF]
JAMA Oncology, 2015 Undoubtedly the discovery of immune checkpoints such as CTLA-4 and PD-1 has been crucial to the development of cancer immunotherapy. Although these molecules were originally discovered as molecules playing a role in T cell activation or apoptosis, subsequent preclinical research showed their important role in the maintenance of peripheral immune ...
John B A G, Haanen, Caroline, Robert
openaire +3 more sources
Cardiotoxicity of Immune Checkpoint Inhibitors [PDF]
Current Oncology Reports, 2021 Immune checkpoint inhibitors (ICIs) have improved the survival of several cancers. However, they may cause a wide range of immune-related adverse events (irAEs). While most irAEs are manageable with temporary cessation of ICI and immunosuppression, cardiovascular toxicity can be associated with high rates of morbidity and mortality.
Rushin P. Patel +6 more
openaire +2 more sources
Immune checkpoint inhibitors in malignancy [PDF]
Australian Prescriber, 2019 Immune checkpoints normally stop the body from mounting an immune response against healthy cells. Some cancers can acquire these checkpoints so that the tumour cells are not recognised by the immune systemInhibiting the checkpoints therefore enables the tumour cells to be recognised and allows an immune response to be activated against themImmune ...
Luke, Ardolino, Anthony, Joshua
openaire +2 more sources
Immune Checkpoint Inhibitors in NSCLC [PDF]
Current Treatment Options in Oncology, 2014 Lung cancer is the leading cause of cancer-related mortality worldwide. Cytotoxic chemotherapy and tyrosine kinase inhibitors provide palliation and prolong survival, however, the median survival for patients with metastatic disease remains poor and more effective therapies are needed.
Douglas B, Johnson +2 more
openaire +2 more sources
Zhongliu Fangzhi Yanjiu, 2020 In recent years, immunotherapy has been continuously developed, and the safety and efficacy of immune checkpoint inhibitors combined with intracranial radiotherapy for melanoma brain metastasis have been initially recognized.
HE Qian, REN Qinglan
doaj +1 more source
Immune Checkpoint Inhibitors in Melanoma [PDF]
Melanoma Management, 2015 The potential to harness the power of the immune system and effectively treat patients with metastatic melanoma is finally being realized with the advent of immune checkpoint inhibitors. These new therapies herald a new era in the treatment of melanoma with the potential to produce very durable responses and possible cure for a subset of patients ...
Adam J, Cooper +2 more
openaire +4 more sources